Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06587490 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Total RadIoTherapy of Oligometastatic caNcerS

Study acronym: TRITONS
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv6
  2. Lead sponsor: Tyler Seibert to University of California, San Diego Primary completion date: Mar 2030 to Nov 2033 · Completion date: Aug 2032 to Nov 2034 · Start date: Nov 1, 2024 to Nov 12, 2024 · 2 morev5 Show 5 more changesShow less
    • Primary completion date: Mar 2030 to Nov 2033
    • Completion date: Aug 2032 to Nov 2034
    • Start date: Nov 1, 2024 to Nov 12, 2024
    • Eligibility criteria expanded, about 42 words
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  3. Study Identification, Study Status, Oversight, Contacts/Locations, IPDSharingv4
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Oct 2024 to Nov 1, 2024v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 2024 to Nov 1, 2024
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase III non-blinded randomized study evaluating patients with oligometastatic cancers (up to 10 metastases). Subjects are randomized 1:1 to stereotactic ablative radiotherapy (SABR) plus standard of care therapies versus standard of care therapies alone. The investigators will measure progression-free survival at 2 years based on the hypothesis that subjects treated with SABR plus standard of care will not experience disease progression for a longer period of time than subjects treated with standard of care alone. The investigators will also measure overall survival and safety of SABR, as well as biomarkers that may help predict, in the future, who will benefit from the SABR treatment.
Trial Details
NCT Number NCT06587490
Lead Sponsor University of California, San Diego
Conditions Oligometastatic Malignant Solid Neoplasm
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov